CP
TYRA icon

Caligan Partners’s Tyra Biosciences TYRA Stock Holding History

Caligan Partners’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$48.9M Buy
1,276,968
+332,711
+35% +$10.8M 3.25% 10
2025
Q4 		$24.8M Buy
944,257
+247,432
+36% +$4.54M 2.04% 11
2025
Q3 		$9.75M Buy
696,825
+506,875
+267% +$5.78M 1.28% 14
2025
Q2 		$1.82M Buy
189,950
+164,950
+660% +$1.57M 0.35% 16
2025
Q1 		$233K Buy
+25,000
New +$324K 0.05% 16

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APMC
Alta Partners Management Company Jackson, Wyoming $151M AUM 296.21% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Caligan Partners's TYRA Position: Q1 2026 in Review

Caligan Partners increased its Tyra Biosciences (TYRA) stake by 35% in Q1 2026, buying an estimated $10.8M and bringing the position to 1,276,968 shares worth $48.9M. The position accounts for 3.25% of the portfolio, ranked #10.

Caligan Partners first reported a position in TYRA in Q1 2025 and has held it in 5 quarters since. 164 funds tracked by Wall St. Rank hold TYRA as of Q1 2026.

  • Caligan Partners held 1,276,968 shares of Tyra Biosciences worth $48.9M as of Q1 2026.
  • Caligan Partners bought 332,711 Tyra Biosciences shares in Q1 2026, an estimated $10.8M.
  • Tyra Biosciences made up 3.25% of Caligan Partners's portfolio in Q1 2026, its #10 holding.
  • Caligan Partners first reported a position in Tyra Biosciences in Q1 2025 and has held it in 5 quarters since.
  • 164 funds tracked by Wall St. Rank held Tyra Biosciences as of Q1 2026.

Based on Caligan Partners's 13F filing for Q1 2026, filed 15 May 2026.